Hopen Life Science Ventures
VC Fund
Grand Rapids, United States
Hopen Life Science Ventures is a VC fund in Grand Rapids focused on Biotechnology and Medical. Hopen Therapeutics is a private investment and management firm focused on helping early- to mid-stage life science developments achieve commercial success. We're interested in promising pharmaceutical and healthcare concepts, and offer idea owners three key advantages: ample funding, development and managerial expertise, and a broad network ofindustry relationships.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Hopen Life Science Ventures invests in
Stages Hopen Life Science Ventures invests in
Countries Hopen Life Science Ventures invests in
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Therapeutics 2 (33%)
- Medical Device 2 (33%)
Stage
- Series A 2 (33%)
- Grant 1 (17%)
- Series B 1 (17%)
- Series C 1 (17%)
- Series D 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $30.4M / Series D / Sep 13, 2022 | |
Cirius Therapeutics
|
Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novelinsulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH.Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States. | $40M / Series A / Apr 11, 2017 | |
|
Delphinus Medical Technologies
|
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. | $39.5M / Series C / Sep 10, 2015 | |
Bjond
|
Bjond Inc. operates in the technology sector. The company was founded in 2012 and is based in Columbus, Ohio.Bjönd is automated workflow, real-time decision support and behavior change software that consumers and businesses use to change outcomes and lives in any industry . . . in any situation.Bjönd is designed to enable anyone - eventhose with little or no technical skills - to build interactive content and automated, expert workflows for any subject. | $3.3M / Series A / Apr 04, 2014 | |
Trapelo Health
|
Trapelo Health is an Information Technology company focused on precision oncology. Trapelo is an innovative decision support platform that aligns the interests of providers, labs, and payors in the appropriate, scalable use of precision medicine - in real-time. | $7.2M / Series B / Jul 18, 2011 | |
Base4 Biotechnology
|
Nymirum is a venture-backed, privately held company that has developed the RNArchitect suite to rapidly solve high-resolution RNA 3D structures and a proprietary drug discovery platform that targets RNA with small molecules. | $2.8M / Grant / Jan 01, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Hopen Life Science Ventures invest in?
Hopen Life Science Ventures invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Grant stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hopen Life Science Ventures last invest?
The most recent investment recorded for Hopen Life Science Ventures closed in Sep 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
